NCT05161195 2026-04-02
Roll-over Study to Allow Continued Access to Ribociclib
Novartis
Phase 4 Active not recruiting
Novartis
University of Ulm
GBG Forschungs GmbH
Eli Lilly and Company
Palleos Healthcare GmbH
AstraZeneca
Eli Lilly and Company
Assiut University